# US 2023/0407262 A1 · High-expression type mesenchymal stem cells, culture method and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0407262 A1
- Document ID: US20230407262A1
- Status: Published application
- Kind: A1
- Application number: 18/055,409
- Filed: 2022-11-14
- Published: 2023-12-21
- Earliest claimed: 2022-06-21
- Assignees: Gwo Xi Stem Cell Applied Technology Co., Ltd.
- Applicants: Gwo Xi Stem Cell Applied Technology Co., Ltd.
- Inventors: Wei Wu Li; Tzyy-Wen Chiou; Horng-Jyh Harn; Shinn-Zong Lin; Ming-Hsi Chuang; Po-Cheng Lin; Chia-Hsin Lee; Mao-Hsuan Huang
- Web page: https://patentgrep.com/patent/US20230407262A1

## CPC

- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/435: from animals; from humans
- C12N 5/0618: {Cells of the nervous system}
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- C12N 5/0619: {Neurons}
- C12N 2502/088: neural stem cells
- C12N 2502/1382: Adipose-derived stem cells [ADSC], adipose stromal stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a medicine for treating a neurodegenerative disease, which employs LEFTY2 (Left-Right Determination Factor 2) generated by co-culturing mesenchymal stem cells of mammals with nerve cells having mutations in the APP (Amyloid precursor protein) gene, or a specific protein. The LEFTY2 has an effect of inhibiting Beta amyloid and a hyperphosphorylated neuronal microtubule-associated protein (Tau protein), without affecting the development of nerve cells and having the ability to promote the growth of the nerve cells; and the two types of proteins have a crucial impact on the neurodegenerative diseases.

## Claims

### Claim 1

A method for culturing high-expression type mesenchymal stem cells, by co-culturing initial mesenchymal stem cells with nerve cells in a first medium for 24 to 196 h; wherein
the initial mesenchymal stem cells can be procured from different sources including adipose tissue, dental pulp, bone marrow tissue and umbilical cord tissue of mammals;
the first medium is a Neurobasal medium comprises B-27 Supplement, N-2 Supplement, L-glutamine, non-essential amino acids, penicillin/streptomycin and heparin;
the nerve cells have mutations in the APP (Amyloid precursor protein) gene; and
the high-expression type mesenchymal stem cells can highly express LEFTY2 (Left-Right Determination Factor 2).

### Claim 2 (depends on 1)

The method for culturing high-expression type mesenchymal stem cells of claim 1, wherein a ratio of the number of the initial mesenchymal stem cells to the number of the nerve cells is between 1:0.01 and 1:100.

### Claim 3 (depends on 1)

The method for culturing high-expression type mesenchymal stem cells of claim 1, wherein the nerve cells are induced pluripotent stem cells produced by reprogramming the somatic cells of a dementia patient, or nerve cells obtained after differentiation of an induced pluripotent stem cell with Trisomy 21.

### Claim 4 (depends on 1)

The method for culturing high-expression type mesenchymal stem cells of claim 1, further comprising: collecting the first medium after the co-culture and performing filtration and concentration to obtain a protein complex, the protein complex comprising at least one of Thrombospondin-1, Galectin-7, Alpha-2-HS-glycoprotein, Sparc protein, Keratin type II cytoskeletal 74, Nucleophosmin and FSTL1 protein (Follistatin-related protein 1).

### Claim 5

A method for culturing high-expression type mesenchymal stem cells, by co-culturing initial mesenchymal stem cells with specific proteins in a second medium for 24 to 196 h, wherein
the initial mesenchymal stem cells can be procured from different sources including adipose tissue, dental pulp, bone marrow tissue and umbilical cord tissue of mammals;
the second medium is a Neurobasal medium comprises B-27 Supplement, N-2 Supplement, L-glutamine, non-essential amino acids, penicillin/streptomycin and heparin;
the specific proteins are at least one of Thrombospondin-1, Galectin-7, Alpha-2-HS-glycoprotein, Sparc protein, Keratin type II cytoskeletal 74, Nucleophosmin and FSTL1 protein; and
the high-expression type mesenchymal stem cells can highly express LEFTY2 (Left-Right Determination Factor 2).

### Claim 6 (depends on 5)

The method for culturing high-expression type mesenchymal stem cells of claim 5, wherein when the number of the initial mesenchymal stem cells is set as X1 and the concentration of the first specific protein in the medium is set as Y1 ng/mL, a ratio of X1 to Y1 is between 1×106:100 and 1×106:1,000.

### Claim 7 (depends on 1)

A High-expression type mesenchymal stem cell, which is prepared by the culturing method of claim 1 and capable of highly expressing LEFTY2.

### Claim 8 (depends on 5)

A High-expression type mesenchymal stem cell, which is prepared by the culturing method of claim 5 and capable of highly expressing LEFTY2.

### Claim 9

A method for producing LEFTY2, comprising the following steps:
a step of co-culturing: initial mesenchymal stem cells are co-cultured with nerve cells in a first medium, or the initial mesenchymal stem cells are co-cultured with specific proteins in a specific medium; and
a step of collecting a finished product: a cell culture solution obtained in the culture process, or high-expression type mesenchymal stem cells obtained in the step of co-culturing are extracted, to obtain LEFTY2; wherein
the animal mesenchymal stem cells can be procured from different sources including adipose tissue, dental pulp, bone marrow tissue and umbilical cord tissue of mammals;
the first medium and the second medium each is a Neurobasal medium comprise B-27 Supplement, N-2 Supplement, L-glutamine, non-essential amino acids, penicillin/streptomycin and heparin;
the nerve cells have mutations in APP gene;
the specific proteins are at least one of Thrombospondin-1, Galectin-7, Alpha-2-HS-glycoprotein, Sparc protein, Keratin type II cytoskeletal 74, Nucleophosmin and FSTL1 protein; and
the high-expression type mesenchymal stem cells can highly express LEFTY2.

### Claim 10

A pharmaceutical composition for treating a neurodegenerative disease, at least comprising LEFTY2 and/or high-expression type mesenchymal stem cells which can highly express LEFTY2.

### Claim 11 (depends on 10)

The pharmaceutical composition for treating a neurodegenerative disease of claim 10, wherein the concentration of the LEFTY2 is greater than 25 ng/mg.

### Claim 12 (depends on 10)

The pharmaceutical composition for treating a neurodegenerative disease of claim 10, wherein the neurodegenerative disease is FTLD (Frontotemporal Lobar Degeneration), Alzheimer's disease, or amyloidosis.
